Wetenschap en Onderzoek

Publicaties

Belangrijkste wetenschappelijke publicaties van de afdeling radiotherapie van het LUMC. 

Laatste update: mei 2018.


Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen Ch, Lutgens LHCW, Smit VT, Singh N, Do V, D’Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. Lancet Oncology. 2018;19(3):295-309.
Impact factor: 33.9, aantal keer geciteerd: 0.
Link naar artikel: https://www.sciencedirect.com/science/article/pii/S1470204518300792?via=ihub

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.  Lancet Oncology. 2016;17(8):1114-26.
Impact factor: 33.9, aantal keer geciteerd: 27.
Link naar artikel: https://www.sciencedirect.com/journal/the-lancet-oncology/vol/17/issue/8 

Endometrial cancer.
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Lancet. 2016 12;387(10023): 1094-108. 
Impact factor: 47.8, aantal keer geciteerd: 131.
Link naar samenvatting: https://www.ncbi.nlm.nih.gov/pubmed/26354523

Organ preservation in rectal cancer: have all questions been answered?
Marijnen CAM.  Lancet Oncology. 2015 Jan;16(1):e13-22.
Impact factor: 33.9, aantal keer geciteerd: 26.
Link naar samenvatting: https://www.ncbi.nlm.nih.gov/pubmed/25638548

No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. 
Wiltink LM, Nout RA, Fiocco M, Meershoek-Klein Kranenbarg E, Jürgenliemk-Schulz IM, Jobsen JJ, Nagtegaal ID, Rutten HJ, van de Velde CJ, Creutzberg CL, Marijnen CAM. Journal of Clinical Oncology. 2015 May 20;33(15):1640-6.
Impact factor: 24.0, aantal keer geciteerd: 21.
Link naar artikel: http://ascopubs.org/doi/full/10.1200/JCO.2014.58.6693

Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.
Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK.  Lancet Oncology. 2014 Feb;15(2):164-71.
Impact factor 33.9, aantal keer geciteerd: 90.
Link naar artikel: https://www.sciencedirect.com/science/article/pii/S1470204513705564?via=ihub

Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance†.
Daniëls LA, Krol ADG, de Graaf MA, Scholte AJ, Van't Veer MB, Putter H, de Roos A, Schalij MJ, Creutzberg CL. Ann Oncol. 2014 Jun;25(6):1198-203.
Impact factor: 11.8, aantal keer geciteerd: 11.
Link naar artikel: https://academic.oup.com/annonc/article/25/6/1198/2769793

Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC.20 randomized trial. 
Chow E, Meyer RM, Chen BE, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Wong RK, Brundage M. Journal of Clinical Oncology. 2014;32(34):3867-73.
impact factor: 24.0, aantal keer geciteerd: 14.
Link naar artikel: http://ascopubs.org/doi/full/10.1200/JCO.2014.57.6264

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncology.
van Gijn W, Marijnen CAM, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ; Dutch Colorectal Cancer Group.  2011 Jun;12(6):575-82.
Impact factor: 33.9, aantal keer geciteerd: 522.
Link naar samenvatting artikel: https://www.ncbi.nlm.nih.gov/pubmed/21596621

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
R.A. Nout, V.T. Smit, H. Putter, I.M. Jürgenliemk-Schulz, J.J. Jobsen, L.C.H.M. Lutgens, E.M. van der Steen-Banasik, J.W. Mens, A. Slot, M.C. Stenfert Kroese, B.N. van Bunningen, A.C. Ansink, W.L. van Putten, C.L. Creutzberg, for the PORTEC Study Group.  Lancet 2010; 375: 816-23.
Impact factor: 47.8, aantal keer geciteerd: 427.Link naar samenvatting artikel: https://www.ncbi.nlm.nih.gov/pubmed/20206777


Publicaties 2018
Publicaties 2017
Publicaties 2016